RareCyte® enables practical deployment of CTC-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation.
- Unbiased, reproducible, highly sensitive, and specific CTC detection
- Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
- Deploy through our global contract research organization (CRO) network or in your own lab
- Utilize cancer-specific panels or Developer panels for CTC biomarker analysis
- Custom assay and companion diagnostics co-development through our Pharma Programs